News
ANAB
--
0.00%
--
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 4d ago
8-K: ANAPTYSBIO, INC
(EDGAR Online via COMTEX) -- 0001370053false00013700532021-01-112021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 05:27
AnaptysBio Expects To Report Cash, Cash Equivalents, Investments Of ~$410M As Of Dec. 31, 2020
-SEC Filing 
SEC Filing  · 01/11 15:42
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Ham...
GlobeNewswire · 01/07 21:15
On Nov. 11, AnaptysBio Terminated Sublease With Trex Enterprises Corp. With Respect To Facilities In San Diego, CA Building
-Reuters
Reuters · 11/17/2020 21:12
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Ham...
GlobeNewswire · 11/13/2020 14:25
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/jeff141/anab/1804050
GlobeNewswire · 11/13/2020 14:25
AnaptysBio EPS misses by $0.15
AnaptysBio (ANAB): Q3 GAAP EPS of -$0.87 misses by $0.15.Cash, cash equivalents and investments of $374.5M.Press Release
Seekingalpha · 11/04/2020 21:52
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
EQNX::TICKER_START (NASDAQ:ANAB), EQNX::TICKER_END
GlobeNewswire · 11/04/2020 21:00
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
EQNX::TICKER_START (NASDAQ:ANAB), EQNX::TICKER_END
GlobeNewswire · 11/04/2020 21:00
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
GlobeNewswire · 11/04/2020 21:00
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Insider Monkey · 10/27/2020 04:54
GlaxoSmithKline, AnaptysBio amend immuno-oncology pact
AnaptysBio (ANAB) and GlaxoSmithKline (GSK) have amended their immuno-oncology collaboration agreement that now provides AnaptysBio with increased royalties on dostarlimab sales, a royalty on GSK’s Zejula and a one-time cash
Seekingalpha · 10/26/2020 12:54
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Ana...
GlobeNewswire · 10/26/2020 12:24
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that AnaptysBio and GlaxoSmithKline (GSK) have amended their immuno-oncology collaboration agreement. The amended agreement provides AnaptysBio with increased royalties on dostarlimab sales under the collaboration, a royalty on GSK's Zejula(TM) and a one-time cash payment. GSK receives freedom to conduct combination development and commercialization of Zejula(TM) with third party molecules.
GlobeNewswire · 10/26/2020 12:24
AnaptysBio, GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in
Benzinga · 10/26/2020 12:05
AnaptysBio (ANAB) Jumps: Stock Rises 7.7%
Zacks · 10/16/2020 14:00
Allscripts Healthcare, Concho Resources: 5 Top Stock Gainers for Wednesday
TheStreet.com · 10/14/2020 21:19
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump
Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39.
Benzinga · 10/14/2020 18:33
Allscripts Healthcare, Concho Resources: 5 Top Stock Gainers for Wednesday
Allscripts, AnaptysBio, Concho Resources, Voxx International and Nio are five top stock gainers for Wednesday.
TheStreet.com · 10/14/2020 18:16
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about AnaptysBio through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
More